All data are based on the daily closing price as of September 2, 2025
g

Gongwin Biopharm Holdings

6617.TWO
3.32 USD
0.08
+2.47%

Overview

Last close
3.32 usd
Market cap
376.73M usd
52 week high
6.11 usd
52 week low
2.23 usd
Target price
N/A usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
362.8232
Price/Book Value
4.9281
Enterprise Value
342.83M usd
EV/Revenue
307.7102
EV/EBITDA
-167.232

Key financials

Revenue TTM
1.12M usd
Gross Profit TTM
354480.29 usd
EBITDA TTM
-5.40M usd
Earnings per Share
-0.02 usd
Dividend
N/A usd
Total assets
N/A usd
Net debt
N/A usd

About

Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of liver cancer; PTS-02 for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion. The company was founded in 2014 and is based in Taipei, Taiwan.
  • Symbol
    6617.TWO
  • Exchange
    TWO
  • Isin
    N/A
  • Country
    Taiwan
  • Sector
    Healthcare
  • Industry
    Biotechnology
  • CEO
  • Headquarter
    Taipei
  • Web site
    https://www.gongwinbiopharm.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top